63498-16-8

Usage

General Description

2-amino-3,5-dibromobenzoyl chloride is a chemical compound that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is a derivative of benzoyl chloride, with the addition of two bromine atoms and an amino group. 2-aMino-3,5-dibroMobenzoyl chloride is a versatile building block for the production of various organic compounds, including dyes and pigments. It is a highly reactive compound that is used in the formation of amides, esters, and other functional groups. Due to its reactivity and potential hazards, 2-amino-3,5-dibromobenzoyl chloride should be handled and stored with caution, in accordance with safe laboratory practices.

Upstream product

• 609-85-8 2-amino-3,5-dibromobenzoic acid 
• 50910-55-9 3,5-dibromo-2-amino benzaldehyde 
• 118-92-3 anthranilic acid 

Downstream Products

• 611-75-6 bromhexine monohydrochloride 

Relevant academic research and scientific papers

Preparation method of bromhexine hydrochloride

The invention provides a preparation method of bromhexine hydrochloride. The method comprises the steps that 2-amino-3, 5-dibromo-benzene and N-methyl cyclohexane are used as the raw material, and bromhexine hydrochloride is obtained after reductive amina

Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase

Halosalicylamide derivatives were identified from high-throughput screening as potent inhibitors of HCV NS5B polymerase. The subsequent structure and activity relationship revealed the absolute requirement of the salicylamide moiety for optimum activity. Methylation of either the hydroxyl group or the amide group of the salicylamide moiety abolished the activity while the substitutions on both phenyl rings are acceptable. The halosalicylamide derivatives were shown to be non-competitive with respect to elongation nucleotide and demonstrated broad genotype activity against genotype 1-3 HCV NS5B polymerases. Inhibitor competition studies indicated an additive binding mode to the initiation pocket that is occupied by the thiadiazine class of compounds and an additive binding mode to the elongation pocket that is occupied by diketoacids, but a mutually exclusive binding mode with respect to the allosteric thumb pocket that is occupied by the benzimidazole class of inhibitors. Therefore, halosalicylamides represent a novel class of allosteric inhibitors of HCV NS5B polymerase.